Chickenpox
MONDO:0005700A contagious childhood disorder caused by the varicella zoster virus. It is transmitted via respiratory secretions and contact with chickenpox blister contents. It presents with a vesicular skin rash, usually associated with fever, headache, and myalgias. The pruritic fluid-filled vesicles occur 10-21 days after exposure and last for 3-4 days. An additional 3-4 days of malaise follows before the affected individual feels better. An individual is contagious 1-2 days prior to the appearance of the blisters until all blisters are crusted over. Generally, healthy individuals recover without complications.
Also known as: Varicella, chicken pox, chicken pox infection, chickenpox, varicella
58 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
MRNA vaccine takes on shingles: could it beat shingrix?
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing a new mRNA vaccine called ABO1108 to prevent shingles in adults aged 40 and above. Around 180 healthy volunteers will receive two shots of either the new vaccine at different doses, a placebo, or the existing Shingrix vaccine. The main goal is to…
Phase: PHASE1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:32 UTC
-
New mRNA shingles vaccine shows promise in Mid-Stage trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new mRNA vaccine called ABO1108 to see if it can prevent shingles in adults aged 40 and above. About 300 healthy volunteers will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the immune response and check for sa…
Phase: PHASE2 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:31 UTC
-
New shingles vaccine candidate enters Mid-Stage trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new shingles vaccine called LYB004 in 840 adults aged 40 and older in China. Participants receive one of four different doses of the vaccine or a placebo. The goal is to see how well the vaccine triggers an immune response and whether it is safe.
Phase: PHASE2 • Sponsor: Guangzhou Patronus Biotech Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:07 UTC
-
New shingles vaccine CRV-101 takes on shingrix in Head-to-Head trial
⭐️ VACCINE ⭐️ OngoingThis phase 2 study tests a new shingles vaccine called CRV-101 (amezosvatein) against the current standard, Shingrix, in about 1,500 adults aged 50 and older. The goal is to see if CRV-101 is safer and triggers a strong immune response. Participants receive two shots and are moni…
Phase: PHASE2 • Sponsor: Curevo Inc • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:53 UTC
-
Engineered immune cells plus chickenpox vaccine take on childhood cancers
Disease control OngoingThis early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hospital at home: new study tests home care for infections
Disease control OngoingThis study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…
Phase: NA • Sponsor: Copenhagen University Hospital at Herlev • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Scientists compare immune responses to viral and bacterial infections in ICU patients
Knowledge-focused OngoingThis study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study aims to uncover hidden dangers of shingles virus in the brain
Knowledge-focused OngoingThis study looks back at medical records of 50 adults who had a shingles virus infection in their brain or spinal cord. Researchers want to find out what makes some people more likely to get these serious infections and what leads to long-term problems like memory loss or seizure…
Sponsor: Kocaeli University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
AI predicts hospital stays, but study never started
Knowledge-focused TerminatedThis study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
AI vs. skin doctors: who diagnoses better?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC